This phase III trial compares the effectiveness of rituximab to mosunetuzumab in treating patients with follicular lymphoma with a low tumor burden. Rituximab …

Classic Follicular LymphomaFollicular Lymphoma With Unusual Cytological Features

~Estimated

~$10 – $5,625

National Cancer Institute (NCI)NCT06337318

Phase 2

TREND-FL: Tafasitamab and Rituximab to Enhance Outcomes in Patients With Newly Diagnosed Follicular Lymphoma

This phase II trial tests how well tafasitamab and rituximab works for the treatment of newly diagnosed follicular lymphoma. Tafasitamab is a monoclonal antibo…

Classic Follicular LymphomaGrade 1 Follicular LymphomaGrade 2 Follicular Lymphoma+1 more

~Estimated

~$10 – $6,250

University of WashingtonNCT07731789